Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – A D-dimer level below 500 ng/mL reliably rules out acute aortic dissection, although the positive predictive value of a higher concentration is quite…
Ben Wolin, CEO and Co-Founder of Everyday Health, talks about innovations in consumer e-marketing, digital patient care and the future of medicine. Follow Everyday Health on Twitter at:…
NEW YORK (Reuters Health) – The anti-EGFR antibody cetuximab added to two state-of-the-art regimens for metastatic colorectal cancer produces favorable response rates with manageable toxicity, a German team…
NEW YORK (Reuters Health) – In older adults, mean serum levels of 25-hydroxyvitamin D are somewhat higher after a year of taking cholecalciferol (vitamin D3) compared to ergocalciferol…
NEW YORK (Reuters Health) – The morbidity of extensive axillary lymph node dissection can be avoided without jeopardizing survival for some breast cancer patients with positive sentinel lymph…
Thomas Goetz, Executive Editor of Wired, talks about “information with feeling” and how the future of health is in the hands of the consumer. Follow Thomas Goetz on…
NEW YORK (Reuters Health) – In a randomized, single-center study of critically ill patients in an intensive care unit, permissive enteral underfeeding was associated with lower morbidity and…
NEW YORK (Reuters Health) – Research shows that biliopancreatic diversion (BPD) significantly reduces renal and cardiovascular complications over 10 years in morbidly obese individuals with newly diagnosed type…
NEW YORK (Reuters Health) – In looking back at patients admitted to a medical ICU in Olmsted County, Minnesota in 2006, clinicians found that those who were on…
NEW YORK (Reuters Health) – In metformin-treated patients with type 2 diabetes, exenatide twice daily improves glycemic control to the same degree as insulin aspart twice daily, but…
